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Abstract
Background: Invasive	candidiasis	 (IC)	 is	a	common	cause	of	mortality	 in	solid	organ	





Results: A	total	of	639	cases	of	 IC	were	 identified.	The	most	common	species	was	






non- albicans	species.	A	high	rate	of	breakthrough	 IC	was	seen	 in	patients	receiving	
antifungal	prophylaxis	(39%).	Factors	associated	with	mortality	include	organ	dysfunc-
tion,	 lung	 transplant,	 and	 treatment	with	a	polyene	antifungal.	The	only	modifiable	
factor	 identified	was	 choice	 of	 antifungal	 drug	 class	 based	 upon	 infecting	Candida 
species.
Conclusion: These	data	highlight	the	common	and	distinct	features	of	IC	in	OTRs.
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1  | INTRODUCTION
Advances	 in	 transplantation	 biology,	 organ	 procurement,	 surgical	
techniques,	and	immunosuppressive	therapy	have	made	organ	trans-







The	 Transplant-Associated	 Infection	 Surveillance	 Network	
(TRANSNET)	was	 established	 in	 2001	 as	 a	 prospective	 surveillance	
group	for	the	purpose	of	understanding	the	burden	of	invasive	fungal	
infections,	and	to	better	define	patients	at	risk	and	outcome	of	these	
infections.14,15	 The	 group	 included	 15	 geographically	 diverse	 trans-
plant	centers	in	the	United	States	that	provided	infection	surveillance	
data	for	invasive	fungal	infections	in	solid	organ	transplant	recipients	




Fifteen	 TRANSNET	 sites	 performed	 transplantation	 and	 provided	
prospective	surveillance	on	these	patients.	The	period	of	IC	infection	
surveillance	was	2001	through	2006,	and	included	all	OTRs	who	de-




2.2 | Definitions and case identification
Only	proven	and	probable	IC	infections	as	defined	by	the	EORTC/MSG	
criteria16,17	 were	 included	 (see	 definitions	 in	 supplemental	 Data	 S1).	
Lower	 urinary	 tract	 infection	 and	 mucosal	 infections	 were	 excluded.	
Cases	 were	 reviewed	 to	 determine	 individual	 case	 validity	 by	 a	 Data	
Review	Committee.	 IC	was	 identified	 prospectively	 among	 this	 popu-
lation	by	establishing	monthly	patient	 logs	of	 transplant	 recipients,	 re-
viewing	pertinent	culture	data	and	histopathology,	as	well	as	through	the	
routine	contact	with	transplant	physicians	and	coordinators.	Case	infor-













survival	 were	 performed	 by	 tabulating	 these	 measures	 in	 the	 sur-
vivor	and	non-	survivor	cohorts.	The	χ2	 test	or	 the	Fisher	exact	 test	
was	 used	 to	 assess	 statistical	 significance	 for	 categorical	 variables	
and	the	Wilcoxon	rank-	sum	test	was	used	for	continuous	variables.	
Multivariable	analyses	of	factors	associated	with	mortality	were	per-













A	 time-	to-	death	 analysis	 was	 also	 performed.	 First,	 a	 univariate	












type,	 and	 survival	 in	OTRs	with	 IC	 overall,	 by	 transplant	 type,	 and	
Candida	species,	are	presented	in	Table	1.	The	rank	order	of	most	fre-
quently	encountered	species	was	Candida albicans	 (46.3%),	followed	





kidney-	pancreas	 (58,	9.1%),	and	 lung	(55,	8.7%)	 (4	cases	were	miss-
ing	organ	 type	 classification).	 The	median	time	 to	onset	 for	 IC	was	
80	days	post	transplantation	(interquartile	range	[IQR]	14-	545	days).	
In	total,	205	infections	were	diagnosed	early	post	transplant	(within	
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30	days)	 and	 411	were	 diagnosed	 late.	 The	mean	 patient	 age	 was	
47.4	years	 and	 the	 majority	 of	 patients	 were	 Caucasian	 (82.2%).	
Several	 comorbidities	were	 common	 in	 cases,	 including	 renal	 (287,	






of	 patients	 received	 a	 triazole,	 compared	with	 an	AmB	 formulation	
(28%)	or	an	echinocandin	(36%).
3.2 | Characteristics of IC among Candida species
Survival	by	Candida	species	varied	as	shown	in	Figure	1.	The	90-	day	
mortality	by	species	was	22.6%	for	C. albicans,	27.7%	for	C. glabrata,	
31.5%	 for	Candida krusei,	 35.2%	 for	C. parapsilosis,	 and	 highest	 for	
Candida tropicalis	 (44%).	 Epidemiological	 features	 in	 patients	 with	
























and	 liver	 transplant	 cohorts	 (heart	 25.5%,	 lung	 36.4%,	 liver	 30.9%,	
pancreas	13.2%,	kidney	22.3%,	kidney-	pancreas	15.5%).	Allograft	re-
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Variable Odds ratio Lower Upper P- value
C. albicans	vs	non-	albicans Candida
Black 0.59 0.35 0.98 .040
Female 0.65 0.44 0.96 .032
Methyprednisolone 0.57 0.33 0.97 .039
Pulmonary	site 3.22 1.26 8.24 .015
CHF 2.14 0.92 5.00 .078
Kidney 0.59 0.39 0.90 .015
Pancreatitis	disease 2.44 1.02 5.81 .045
Triazole	therapy 0.37 0.24 0.57 <.001
C. albicans	vs	C. glabrata
Black 0.57 0.31 1.03 .063
Female 0.46 0.29 0.72 .001
Age 0.98 0.97 1.00 .028
Methyprednisolone 0.42 0.24 0.74 .003
Triazole	prophylaxis 0.39 0.24 0.62 <.001
Candida parapsilosis	vs	non-	parapsilosis Candida
Age 0.98 0.96 0.99 .011
Early	disease 0.43 0.19 0.95 .037















635 583 548 521 499 483 468
296 279 263 251 242 234 229
155 142 130 121 115 113 113
19 14 14 14 13 13 13
51 46 44 42 39 37 33
25 22 19 18 17 15 14
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the	diaphragm	 (pancreas	26.3%,	 liver	20.7%,	kidney-	pancreas	19%).	
Antifungal	prophylaxis	was	common	among	all	OTRs	with	 IC	 (39%);	
however,	 this	practice	was	most	common	for	 the	heart	and	 lung	al-
lograft	recipients	(heart	64.8%,	lung	70.9%	vs	pancreas	28.9%,	kidney	
29.9%,	liver	44.8%,	and	kidney-	pancreas	51.7%).	Among	patients	who	




observed	predominantly	 in	 the	 liver	 transplant	cohort	 (amphotericin	
33/261	12.6%	and	echinocandin	14/261	5.4%).
Triazoles	were	the	most	common	antifungal	drugs	used	for	treat-
ment	 of	 IC.	 This	 treatment	 was	 particularly	 frequent	 in	 pancreas	
(28/38;	 73.7%)	 and	 kidney	 transplant	 recipients	 (158/224;	 70.5%).	
Additional	characteristics	in	the	different	transplant	types	are	shown	
in	Table	S1.
3.4 | Predictors of mortality in patients with IC
Ninety-	day	mortality	 for	all	patients	was	168/635	 (26.5%).	Kaplan–
Meier	estimate	of	30-	day	survival	was	85.5%.	Survival	was	 statisti-
cally	 different	 among	 Candida	 species	 (Figure	1).	 The	 mortality	 for	





IC	 across	 all	Candida	 species	 included	 renal	 impairment,	 congestive	
heart	 failure,	 lung	 transplant,	 and	 treatment	with	 an	AmB	 formula-
tion	 (Table	3).	 Prednisone	use	 and	 IC	 in	 the	 early	 transplant	 period	
(30	days)	were	associated	with	reduced	risk	of	mortality.
We	performed	several	subgroup	analyses	to	explore	unique	out-
come	 factors	 based	 on	Candida	 species,	 organ	 transplant	 type,	 and	
infection	 site	 (Table	4).	 The	 majority	 of	 elements	 correlating	 with	




















renal	 insufficiency,	 one-	fourth	 had	hepatic	dysfunction,	 nearly	 50%	
had	diabetes,	and	30%	had	malnutrition.	Nearly	40%	experienced	epi-
sodes	of	rejection,	which	may	have	contributed	to	the	prevalence	of	
organ	dysfunction	either	 caused	by	 rejection	or	 anti-	rejection	 ther-
apy.	Furthermore,	a	large	percentage	of	patients	had	received	antifun-
gal	prophylaxis	prior	to	development	of	IC.
Against	 this	 backdrop,	 we	 found	 that,	 similar	 to	 other	 epidemio-
logic	 studies	 of	 IC,	C. albicans	 remained	 the	most	 frequent	 pathogen.	
However,	 >10%	 of	 cases	 included	 infection	with	 2	 or	 more	 Candida 
species.	 The	 frequency	 in	 the	 present	 study	 is	 more	 than	 twice	 that	






antifungals	owing	 to	differences	 in	 susceptibility,	 in	particular,	 the	 re-
duced	susceptibility	of	C. glabrata	and	C. parapsilosis	to	triazole	and	echi-
















Indeed,	 the	mortality	 rate	 in	 the	 transplant	 population	 infected	with	
C. parapsilosis	 was	 unusually	 high	 compared	 to	 previous	 reports.44,45 






transplant	 recipients	 above	 the	 fifth	 decade	 in	 this	 cohort	 (50.2%	
age	>50	at	time	of	transplant).	Two	additional	unique	C. glabrata	risk	























Examination	 of	 antifungal	 choice	 for	 prophylaxis	 and	 therapy	 in	
the	 current	 population	 revealed	 a	 use	 pattern	 consistent	with	 prior	














ratio Lower Upper P- value
Candida	species	subgroup
All	species
Liver	transplant 1.63 0.96 2.76 .071
Renal	insufficiency 2.31 1.46 3.66 <.001
Hepatic	insufficiency 1.68 0.97 2.91 .066
CHF 3.54 1.61 7.81 .002
Pulmonary	site 2.88 1.35 6.16 .006
Prednisone 0.39 0.25 0.63 <.001
Amphotericin	B 1.99 1.24 3.2 .004
Early	disease 0.51 0.3 0.84 .009
C. albicans
Heart	transplant 0.13 0.03 0.55 .006
Renal	insufficiency 3.77 1.82 7.8 <.001
CHF 3.49 1.2 10.11 .022
Pulmonary	site 2.88 0.86 9.66 .088
Disseminated	site 8.66 1.74 43.01 .008
Prednisone 0.37 0.17 0.8 .012
Methyprednisolone 2.61 0.98 6.93 .054
Amphotericin	B 2.85 1.31 6.22 .009
Echinocandin 3.25 1.4 7.58 .006
Early	disease 0.36 0.15 0.85 .021
C. glabrata
Age 1.05 1.02 1.09 .005
Pancreas	transplant 9.84 1.46 66.26 .019
CHF 25.06 2.71 232.13 .005
Pulmonary	site 5.17 0.68 39.49 .113
Prednisone 0.45 0.18 1.15 .094
Echinocandin 0.4 0.17 0.97 .042
Non-	albicans Candida
Heart 3.86 1.14 13.05 .03
Hepatic	insufficiency 3.25 1.6 6.58 .001
CHF 9.02 1.67 48.57 .011
Pulmonary	site 5.01 1.76 14.28 .003
Prednisone 0.48 0.25 0.93 .029
Early	disease 0.54 0.27 1.09 .084
Transplant	organ	subgroups
Kidney
Hepatic	insufficiency 17.28 4.42 67.53 <.001
CHF 6.29 1.89 20.93 .003
Renal	insufficiency 3.63 1.39 9.44 .008
Prednisone 0.2 0.07 0.57 .003
Amphotericin 5.47 1.89 15.86 .002
Echinocandin 5.91 0.74 47.14 .093
Variable
Odds 
ratio Lower Upper P- value
Liver
Renal	insufficiency 3.12 1.54 6.32 .002
CMV 13.96 3.2 60.88 <.001
COPD 0.24 0.07 0.84 .026
Disseminated	site 4.3 0.92 20.06 .063
Prednisone 0.27 0.13 0.6 .001
Methyprednisolone 0.28 0.09 0.89 .032
Early	disease 0.39 0.18 0.86 .02
Candidemia	subgroup
Renal	insufficiency 2.24 1.39 3.61 <.001
CHF 3.11 1.38 7.02 .006
Prednisone 0.41 0.25 0.68 <.001
Amphotericin 2.63 1.59 4.37 <.001
Echinocandin 2.01 1.22 3.3 .006
Early	disease 0.46 0.27 0.8 .006
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TABLE  4 Characteristics	of	OTRs	with	invasive	candidiasis	based	upon	transplant	organ
Variable Heart Lung Pancreas Kidney Liver Kidney- pancreas
Demographics
Age,	mean±SD 52.8±19.3 48.2±15.7 44.5±7.5 48.1±12.9 46.9±17.1 42.6±9.1
Male 35/48	(72.9) 22/54	(40.7) 19/37	(51.4) 112/222	(50.5) 164/259	(63.3) 30/58	(51.7)
Female 13/48	(27.1) 32/54	(59.3) 18/37	(48.6) 110/222	(49.5) 95/259	(36.7) 28/58	(48.3)
Race
Caucasian 39	(83.0) 43	(78.2) 37	(97.4) 167	(74.6) 204	(78.8) 48	(82.8)
Black 3	(6.4) 7	(12.7) 0	(0.0) 43	(19.2) 23	(8.9) 7	(12.1)
Other 5	(10.6) 5	(9.1) 1	(2.6) 14	(6.2) 32	(12.4) 3	(5.2)
Comorbidities
Neutropenia 1/48	(2.1) 1/55	(1.8) 2/38	(5.3) 7/224	(3.1) 12/261	(4.6) 2/58	(3.4)
Fever 20/48	(41.7) 19/55	(34.5) 26/38	(68.4) 115/224	(51.3) 148/261	(56.7) 34/58	(58.6)
Organ	rejection 25/48	(52.1) 22/55	(40.0) 12/37	(32.4) 87/224	(38.8) 88/260	(33.8) 24/58	(41.4)
CMV 4/48	(8.3) 4/55	(7.3) 2/38	(5.3) 12/224	(5.4) 20/261	(7.7) 3/58	(5.2)
Renal	insufficiency 33/48	(68.8) 23/55	(41.8) 8/38	(21.1) 106/224	(47.3) 116/261	(44.4) 22/58	(37.9)
Hepatic	insufficiency 6/48	(12.5) 2/55	(3.6) 1/38	(2.6) 29/224	(12.9) 111/261	(42.5) 6/58	(10.3)
Malnutrition 4/48	(8.3) 10/55	(18.2) 6/38	(15.8) 67/224	(29.9) 95/261	(36.4) 19/58	(32.8)
Diabetes 28/48	(58.3) 18/55	(32.7) 12/38	(31.6) 108/224	(48.2) 130/261	(49.8) 26/58	(44.8)
COPD 3/48	(6.2) 13/55	(23.6) 0/38	(0.0) 16/224	(7.1) 29/261	(11.1) 3/58	(5.2)
CHF 9/48	(18.8) 3/55	(5.5) 2/38	(5.3) 25/224	(11.2) 12/261	(4.6) 5/58	(8.6)
Autoimmune 3/48	(6.2) 6/55	(10.9) 0/38	(0.0) 19/224	(8.5) 15/261	(5.7) 2/58	(3.4)
Pancreatitis 2/48	(4.2) 0/55	(0.0) 2/38	(5.3) 30/224	(13.4) 11/261	(4.2) 11/58	(19.0)
HIV/AIDS 0/48	(0.0) 0/55	(0.0) 0/38	(0.0) 2/224	(0.9) 0/261	(0.0) 0/58	(0.0)
Prednisone 31/48	(64.6) 45/55	(81.8) 26/38	(68.4) 178/224	(79.5) 180/261	(69.0) 43/58	(74.1)
MPS 16/48	(33.3) 10/55	(18.2) 6/38	(15.8) 33/224	(14.7) 42/261	(16.1) 8/58	(13.8)
Candida	species
C. albicans 25	(53.2) 30	(54.5) 18	(47.4) 95	(42.4) 124	(47.9) 27	(46.6)
C. glabrata 9	(19.1) 9	(16.4) 13	(34.2) 62	(27.7) 57	(22.0) 18	(31.0)
C. krusei 2	(4.3) 0	(0.0) 1	(2.6) 6	(2.7) 9	(3.5) 1	(1.7)
C. parapsilosis 4	(8.5) 6	(10.9) 3	(7.9) 22	(9.8) 15	(5.8) 3	(5.2)
C. tropicalis 1	(2.1) 6	(10.9) 0	(0.0) 7	(3.1) 10	(3.9) 1	(1.7)
C. lusitaniae 1	(2.1) 0	(0.0) 0	(0.0) 3	(1.3) 1	(0.4) 0	(0.0)
Multiple 3	(6.4) 3	(5.5) 3	(7.9) 21	(9.4) 38	(14.7) 6	(10.3)
Other 1	(2.1) 0	(0.0) 0	(0.0) 3	(1.3) 4	(1.5) 1	(1.7)
Unspecified 1	(2.1) 1	(1.8) 0	(0.0) 5	(2.2) 1	(0.4) 1	(1.7)
Infection	site
Bloodstream 31/48	(64.6) 29/55	(52.7) 12/38	(31.6) 99/224	(44.2) 107/261	(41.0) 15/58	(25.9)
Abdominal 0/48	(0.0) 0/55	(00.0) 10/38	(26.3) 26/224	(11.6) 54/261	(20.7) 11/58	(19.0)
Pulmonary 4/48	(8.3) 17/55	(30.9) 1/38	(2.6) 3/224	(1.3) 9/261	(3.4) 1/58	(1.7)
Disseminated 3/48	(6.2) 0/55	(0.0) 1/38	(2.6) 9/224	(4.0) 10/261	(3.8) 2/58	(3.4)
CNS 0/48	(0.0) 0/55	(0.0) 0/38	(0.0) 3/224	(1.3) 1/261	(0.4) 0/58	(0.0)
Antifungal	therapy1
Triazole 31/48	(64.6) 38/55	(69.1) 28/38	(73.7) 158/224	(70.5) 158/261	(60.5) 39/58	(67.2)
Amphotericin 14/48	(29.2) 15/55	(27.3) 9/38	(23.7) 59/224	(26.3) 82/261	(31.4) 17/58	(29.3)
Echinocandin 13/48	(27.1) 10/55	(18.2) 14/38	(36.8) 85/224	(37.9) 102/261	(39.1) 24/58	(41.4)
(Continues)
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C. glabrata	was	common.	This	observation	is	congruent	with	previously	
reported	prophylaxis	studies.18	Interestingly,	we	also	found	an	associ-

























the	 importance	of	 a	high	 index	of	 suspicion	 in	 this	 complex	patient	
population.	 In	particular,	 the	presence	of	organ	dysfunction	and	 re-
jection	 should	 prompt	 surveillance	 for	 this	 infectious	 complication.	
Furthermore,	these	observations	highlight	the	need	for	improved	fun-
gal	diagnostics	and	more	effective	antifungal	compounds.
The	 TRANSNET	 database	 is	 comprehensive,	 but	 it	 has	 several	
limitations.	 Baseline	 and	 longitudinal	 laboratory	 data	 were	 minimal	
and	 specific	 information	 about	 drug	 exposure	was	 incomplete.	 For	
example,	information	regarding	antifungal,	antiviral,	and	antibacterial	
prophylaxis	was	limited,	as	were	data	pertaining	to	vascular	catheter	
management,	 immunosuppressive	 regimens,	 and	 institution-	specific	
practices	and	protocols.	It	is	possible	that	information	regarding	cath-
eters	may	 have	 shed	 light	 on	 the	 relatively	 high	mortality	 linked	 to	
C. parapsilosis	infection.	Moreover,	the	dataset	does	not	include	data	
on	 disease	 severity	 and	 transplant	 incompatibility	 characteristics.	




















	 3.	 Al-Hasan	 MN,	 Razonable	 RR,	 Eckel-Passow	 JE,	 Baddour	 LM.	
Incidence	 rate	 and	 outcome	of	Gram-	negative	 bloodstream	 infec-
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	 7.	 Paya	CV.	Fungal	 infections	in	solid-	organ	transplantation.	Clin Infect 
Dis.	1993;16:677–688.
	 8.	 Fortun	J,	Lopez-San	Roman	A,	Velasco	JJ,	et	al.	Selection	of	Candida 
glabrata	 strains	 with	 reduced	 susceptibility	 to	 azoles	 in	 four	 liver	





stay,	 and	 cost	 due	 to	 candidemia:	 a	 case-	control	 study	 using	 data	
from	population-	based	 candidemia	 surveillance.	 Infect Control Hosp 
Epidemiol.	2005;26:540–547.
Variable Heart Lung Pancreas Kidney Liver Kidney- pancreas
Antifungal	prophylaxis
Triazole 19/48	(39.6) 24/55	(43.6) 11/38	(28.9) 58/224	(25.9) 70/261	(26.8) 26/58	(44.8)
Amphotericin 2/48	(4.2) 12/55	(21.8) 0/38	(0.0) 2/224	(0.9) 33/261	(12.6) 1/58	(1.7)
Echinocandin 1/48	(2.1) 3/55	(5.5) 0/38	(0.0) 7/224	(3.1) 14/261	(5.4) 3/58	(5.2)
1Includes	sequential	or	combination	therapy.
OTR,	organ	 transplant	 recipient;	SD,	 standard	deviation;	CMV,	cytomegalovirus,	COPD,	chronic	obstructive	pulmonary	disease;	CHF,	congestive	heart	
failure;	HIV/AIDS,	human	immunodeficiency	virus/acquired	immunodeficiency	syndrome;	MPS,	methylprednisolone;	CNS,	central	nervous	system.
TABLE  4  (Continued)
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